Ibex Medical Analytics, the artificial intelligence (AI)-based cancer diagnostics firm, and KSM, the Research and Innovation Centre of Maccabi Healthcare Services, an Israeli HMO, has deployed Galen Gastric at Maccabi’s pathology institute, meaning it now uses AI for detecting cancer in the gastrointestinal (GI) tract.
Gastric cancer is among the most common malignant diseases in both men and women worldwide, with over a million new cases each year. Pathologists play a crucial role in the detection and diagnosis of cancer, with their assessments being vital for reaching correct treatment decisions by oncologists and improving patient survival rates. However, a rise in cancer prevalence and advances in personalised medicine have resulted in growing diagnostic complexity that significantly increases pathologists’ workloads. In recent years, as pathology labs transition towards digital solutions, pathologists can implement AI-enhanced workflows to improve quality and efficiency of cancer diagnosis, resulting in better patient care.
Ibex harnesses Strong AI and Machine Learning technology. Its Galen platform helps pathologists improve the quality of cancer diagnosis, implement real-time quality control, reduces turnaround time and boosts productivity.
Galen Gastric is an integrated diagnostics and quality control solution that supports pathologists in the detection of gastric cancer, dysplasia, H. pylori and other important clinical findings. The solution is an addition to Galen Prostate and Galen Breast that have already been deployed at Maccabi Healthcare Services, as well as other labs worldwide, where they are used in everyday clinical practice. With this deployment, Maccabi becomes the only health system in the world to use AI for multi-tissue cancer detection on breast, prostate and gastric biopsies, supporting their pathologists with improved accuracy, quality control and efficiency.
Judith Sandbank, MD, director of the Pathology Institute at Maccabi Healthcare Services, said: "We are excited to add Galen Gastric to what is the most comprehensive AI deployment in pathology, supporting us in providing quality diagnosis to our patients. The clinical benefits from using Ibex’s AI solutions have been the key driver in Maccabi’s decision to fully adopt digital pathology, and we are impressed by how fast AI technology has become an indispensable part of our diagnostic pathway. We look forward to benefiting from its new insights in everyday practice.”
Dr Chaim Linhart, co-founder and CTO of Ibex added: “Galen Gastric demonstrates that our Strong AI is the leading approach for empowering pathologists with solutions that support their real-world needs. The Galen platform, recently granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA), lays the foundation to clinical-grade computational solutions that accurately identify dozens of features and become the physician’s perfect companion, helping provide every patient with an accurate, timely and personalised cancer diagnosis.”
Ibex will exhibit in the 33rd European Congress of Pathology, taking place virtually between August 29 and August 31.
